Swiss startup Atlas Bio secures $12.5M to tackle drug development’s 70% failure rate and move beyond animal testing
Swiss tech-bio firm Atlas Bio launched from stealth with $12.5 million in combined pre-seed and seed funding led by Creandum and First Momentum Ventures to reduce drug development failure rates and move beyond animal testing. It's a European biotech deep-tech round relevant to medtech and life-science founders.